newsfilter
← Latest News
GlobeNewswire·

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

  • Neuronetics, Inc. granted inducement restricted stock unit awards to one non-executive employee, Julia Roussel, as a material inducement for employment.
  • Julia Roussel received 9,000 RSUs under the 2020 Inducement Incentive Plan, with vesting scheduled at one-third on each of the first, second, & third anniversaries of the grant date.
  • All vesting is contingent on the recipient's continued service with the Company through the respective vesting dates & approval by the Compensation Committee per NASDAQ Listing Rule 5635(c)(4).
  • Neuronetics operates the NeuroStar Advanced Therapy system, a non-drug, noninvasive TMS treatment cleared by the FDA for major depressive disorder in adults, anxiety symptoms in anxious depression, & as a first-line adjunct for adolescents aged 15-21.
  • The company's Greenbrook network provides direct patient care offering both NeuroStar TMS & SPRAVATO esketamine nasal spray therapies for treatment-resistant depression & acute suicidal ideation.
  • SPRAVATO indications do not demonstrate effectiveness in preventing suicide or reducing suicidal ideation/behavior, & use of the drug does not preclude the need for hospitalization.
Company
Neuronetics
Keywords
Nasdaq:STIM, Neuronetics